资讯
3 天
Zacks.com on MSNCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
1 天
NDTV Profit on MSNCipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug SectorCipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...
In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...
One person using Mounjaro revealed they had a peculiar ‘magic mushroom’ sensation when starting the medication in a discussion about side effects on Reddit ...
In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...
Once users stop taking Mounjaro, their appetite is no longer suppressed, and there's a decent chance that they will revert ...
Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...
5 天
TipRanks on MSNUBS Reiterates Buy Rating on Eli Lilly Stock (LLY) as Weight-Loss Drug Sales AccelerateUBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果